These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
615 related articles for article (PubMed ID: 28460112)
1. Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia. Aponte S; Guerra ÁP; Álvarez-Larrotta C; Bernal SD; Restrepo C; González C; Yasnot MF; Knudson-Ospina A Trans R Soc Trop Med Hyg; 2017 Feb; 111(2):71-80. PubMed ID: 28460112 [TBL] [Abstract][Full Text] [Related]
2. Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia. Otienoburu SD; Maïga-Ascofaré O; Schramm B; Jullien V; Jones JJ; Zolia YM; Houzé P; Ashley EA; Kiechel JR; Guérin PJ; Le Bras J; Houzé S Malar J; 2016 Sep; 15(1):452. PubMed ID: 27596849 [TBL] [Abstract][Full Text] [Related]
3. Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine. Lekana-Douki JB; Dinzouna Boutamba SD; Zatra R; Zang Edou SE; Ekomy H; Bisvigou U; Toure-Ndouo FS Infect Genet Evol; 2011 Mar; 11(2):512-7. PubMed ID: 21251998 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and K13-propeller polymorphisms in Luanda, Angola. Kiaco K; Teixeira J; Machado M; do Rosário V; Lopes D Malar J; 2015 Dec; 14():504. PubMed ID: 26670642 [TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Venkatesan M; Gadalla NB; Stepniewska K; Dahal P; Nsanzabana C; Moriera C; Price RN; Mårtensson A; Rosenthal PJ; Dorsey G; Sutherland CJ; Guérin P; Davis TME; Ménard D; Adam I; Ademowo G; Arze C; Baliraine FN; Berens-Riha N; Björkman A; Borrmann S; Checchi F; Desai M; Dhorda M; Djimdé AA; El-Sayed BB; Eshetu T; Eyase F; Falade C; Faucher JF; Fröberg G; Grivoyannis A; Hamour S; Houzé S; Johnson J; Kamugisha E; Kariuki S; Kiechel JR; Kironde F; Kofoed PE; LeBras J; Malmberg M; Mwai L; Ngasala B; Nosten F; Nsobya SL; Nzila A; Oguike M; Otienoburu SD; Ogutu B; Ouédraogo JB; Piola P; Rombo L; Schramm B; Somé AF; Thwing J; Ursing J; Wong RPM; Zeynudin A; Zongo I; Plowe CV; Sibley CH; Asaq Molecular Marker Study Group Am J Trop Med Hyg; 2014 Oct; 91(4):833-843. PubMed ID: 25048375 [TBL] [Abstract][Full Text] [Related]
7. Selection of N86F184D1246 haplotype of Pfmrd1 gene by artemether-lumefantrine drug pressure on Plasmodium falciparum populations in Senegal. Mbaye A; Dieye B; Ndiaye YD; Bei AK; Muna A; Deme AB; Yade MS; Diongue K; Gaye A; Ndiaye IM; Ndiaye T; Sy M; Diallo MA; Badiane AS; Ndiaye M; Seck MC; Sy N; Koita O; Krogstad DJ; Nwakanma D; Ndiaye D Malar J; 2016 Aug; 15(1):433. PubMed ID: 27562216 [TBL] [Abstract][Full Text] [Related]
8. Montenegro M; Neal AT; Posada M; De Las Salas B; Lopera-Mesa TM; Fairhurst RM; Tobon-Castaño A Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947476 [TBL] [Abstract][Full Text] [Related]
9. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Lim P; Alker AP; Khim N; Shah NK; Incardona S; Doung S; Yi P; Bouth DM; Bouchier C; Puijalon OM; Meshnick SR; Wongsrichanalai C; Fandeur T; Le Bras J; Ringwald P; Ariey F Malar J; 2009 Jan; 8():11. PubMed ID: 19138391 [TBL] [Abstract][Full Text] [Related]
10. Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda. Balikagala B; Mita T; Ikeda M; Sakurai M; Yatsushiro S; Takahashi N; Tachibana SI; Auma M; Ntege EH; Ito D; Takashima E; Palacpac NM; Egwang TG; Onen JO; Kataoka M; Kimura E; Horii T; Tsuboi T Malar J; 2017 Jan; 16(1):23. PubMed ID: 28068997 [TBL] [Abstract][Full Text] [Related]
11. Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study. Ebstie YA; Zeynudin A; Belachew T; Desalegn Z; Suleman S Malar J; 2015 Jun; 14():236. PubMed ID: 26045199 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria from three highly malarious states in India. Bharti PK; Shukla MM; Ringwald P; Krishna S; Singh PP; Yadav A; Mishra S; Gahlot U; Malaiya JP; Kumar A; Prasad S; Baghel P; Singh M; Vadadi J; Singh MP; Bustos MD; Ortega LI; Christophel EM; Kashyotia SS; Sonal GS; Singh N Malar J; 2016 Oct; 15(1):498. PubMed ID: 27737665 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea. Tavul L; Hetzel MW; Teliki A; Walsh D; Kiniboro B; Rare L; Pulford J; Siba PM; Karl S; Makita L; Robinson L; Kattenberg JH; Laman M; Oswyn G; Mueller I Malar J; 2018 Oct; 17(1):350. PubMed ID: 30290825 [TBL] [Abstract][Full Text] [Related]
14. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). Sisowath C; Strömberg J; Mårtensson A; Msellem M; Obondo C; Björkman A; Gil JP J Infect Dis; 2005 Mar; 191(6):1014-7. PubMed ID: 15717281 [TBL] [Abstract][Full Text] [Related]
15. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. Sisowath C; Petersen I; Veiga MI; Mårtensson A; Premji Z; Björkman A; Fidock DA; Gil JP J Infect Dis; 2009 Mar; 199(5):750-7. PubMed ID: 19210165 [TBL] [Abstract][Full Text] [Related]
16. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam. Phong NC; Chavchich M; Quang HH; San NN; Birrell GW; Chuang I; Martin NJ; Manh ND; Edstein MD Malar J; 2019 Jan; 18(1):10. PubMed ID: 30654808 [TBL] [Abstract][Full Text] [Related]
17. Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya. Achieng AO; Muiruri P; Ingasia LA; Opot BH; Juma DW; Yeda R; Ngalah BS; Ogutu BR; Andagalu B; Akala HM; Kamau E Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):92-9. PubMed ID: 26236581 [TBL] [Abstract][Full Text] [Related]
18. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malmberg M; Ngasala B; Ferreira PE; Larsson E; Jovel I; Hjalmarsson A; Petzold M; Premji Z; Gil JP; Björkman A; Mårtensson A Malar J; 2013 Mar; 12():103. PubMed ID: 23506218 [TBL] [Abstract][Full Text] [Related]
19. The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine. Djimde AA; Makanga M; Kuhen K; Hamed K Expert Rev Anti Infect Ther; 2015 Aug; 13(8):1031-45. PubMed ID: 26081265 [TBL] [Abstract][Full Text] [Related]
20. Assessing the therapeutic efficacy of artemether-lumefantrine for uncomplicated malaria in Lagos, Nigeria: a comprehensive study on treatment response and resistance markers. Oyebola KM; Ligali FC; Owoloye AJ; Aina OO; Alo YM; Erinwusi B; Olufemi MJ; Salako BL Malar J; 2024 Aug; 23(1):261. PubMed ID: 39210367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]